Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. develops anti-inflammatory therapeutics that target the complement system through proprietary anti-C5a and anti-C5aR technologies. Its lead program, izicopan, is an orally administered small-molecule inhibitor of C5a-induced signaling via the C5a receptor, and vilobelimab is an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a.
Company news commonly covers izicopan clinical-development strategy, preclinical pharmacology data, complement-mediated inflammatory disease programs, financial results, ordinary-share financings, Nasdaq listing compliance, annual meeting matters and investor communications. Updates also address the company’s operating group, which includes wholly owned subsidiaries in Germany and the United States.
InflaRx (Nasdaq: IFRX) reported promising initial data from the Phase II trial of IFX-1, showing a 50% lower all-cause mortality rate in patients with severe COVID-19 pneumonia compared to best supportive care. The company plans to advance to a Phase III trial with around 360 patients, aiming for a primary endpoint of 28-day all-cause mortality. The Phase II trial revealed a mortality rate of 13% in the IFX-1 group versus 27% in the control group. Interim analysis for the Phase III trial is expected after enrolling 180 patients.